Kevin J. Appelbaum - Mar 31, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Mark Heinen, Attorney-in-Fact for Kevin J. Appelbaum
Stock symbol: BTTX
Transactions as of: Mar 31, 2022
Transactions value $: $4,921
Form type: 4
Date filed: 4/4/2022, 04:27 PM
Previous filing: Dec 22, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Purchase	$4.92K	+2.5K	+66.67%	$1.97	6.25K	Mar 31, 2022	Direct	F1
holding	BTTX	Common Stock						2.41M	Mar 31, 2022	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTTX	Stock Option (Right to Buy)	Award	$0	+235K		$0.00	235K	Apr 1, 2022	Common Stock	235K	$1.97	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.96 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2	These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.
F3	The stock option vests as to 1/4 of the shares subject to the stock option on April 1, 2023 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on April 1, 2022.